Author

J.M. Abascal Junquera

Observed names: Abascal Junquera, Jose Maria, Abascal, Jose Maria, J. M. Abascal, J.M Abascal, J.M. Abascal, J.M. Abascal-Junquera, J.Mª. Abascal Junquera, JM Abascal Junquera, Jose M. Abascal, Jose M. Abascal Junquera, Jose Maria Abascal, Jose Maria Abascal Junquera, Jose María Abascal, Jose María Abascal-Junquera, José M Abascal, José M. Abascal, José M. Abascal García, José M. Abascal Junquera, José M. Abascal-Junquera, José Manuel Abascal, José Maria Abascal, José María Abascal, José María Abascal Junquera, José María Abascal-Junquera, Junquera J.M. Abascal, Junquera JM Abascal

Observed institutions: Universitat Autònoma de Barcelona, Universitat Pompeu Fabra, Vall d'Hebron Hospital Universitari, Hospital Del Mar, Parc de Salut, Hospital Universitario Central de Asturias, Municipal Institute for Medical Research, Hospital del Mar Research Institute

ORCID: 0000-0001-8374-6593

Observed ORCID: 0000-0001-8374-6593

OpenAlex ID: A5006036574

Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer

2007 · Juan Morote, Jacques Planas Morin, et al. · Urology · 185

Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression

2006 · Juan Morote, Anna Orsola, et al. · The Journal of Urology · 96

Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

2006 · Juan Morote, Salvador Esquena, et al. · Urologia Internationalis · 65

Osteoporosis during Continuous Androgen Deprivation: Influence of the Modality and Length of Treatment

2003 · J Morote, E Martinez, et al. · European Urology · 63

Nadir prostate‐specific antigen best predicts the progression to androgen‐independent prostate cancer

2004 · Juan Morote, Enrique Trilla, et al. · International Journal of Cancer · 55

PDF

The Barcelona Predictive Model of Clinically Significant Prostate Cancer

2022 · Juan Morote, Angel Borque-Fernando, et al. · Cancers · 42

PDF

Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non‐muscle‐invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study

2014 · Juan Palou, Carlos Hernández, et al. · British Journal of Urology · 40

2019 · A. Sureda, L. Fumadó, et al. · Health and Quality of Life Outcomes · 29

PDF

Resección transuretral de próstata bipolar vs monopolar: análisis peroperatorio de los resultados

2006 · J.Mª. Abascal Junquera, L. Cecchini Rosell, et al. · Actas Urológicas Españolas · 28

Gastric Cancer in Augmentation Gastrocystoplasty

2005 · Salvador Esquena Fernández, José María Abascal, et al. · Urologia Internationalis · 22

The Percentage of Free Prostatic-Specific Antigen Is Also Useful in Men with Normal Digital Rectal Examination and Serum Prostatic-Specific Antigen between 10.1 and 20 ng/ml

2002 · Juan Morote, Enrique Trilla, et al. · European Urology · 22

Integrating radiological and clinical data for clinically significant prostate cancer detection with machine learning techniques

2025 · Luis Mariano Esteban, Ángel Borque-Fernando, et al. · Scientific Reports · 21

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand

2022 · Juan Morote, Ángel Borque-Fernando, et al. · Cancers · 21

PDF

Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer

2005 · J. Morote, S. Esquena, et al. · The International Journal of Biological Markers · 17

Sentinel Lymph Node Biopsy in Prostate Cancer Using the SENSEI® Drop-In Gamma Probe

2021 · Jose Maria Abascal Junquera, Antoni Mestre-Fusco, et al. · Clinical Nuclear Medicine · 16

Diagnóstico fotodinámico con hexaminolevulinato en el cáncer vesical no músculo invasivo: experiencia del grupo BLUE

2011 · J.P. Burgués, G. Conde, et al. · Actas Urológicas Españolas · 16

PDF

A Drop-in Gamma Probe for Minimally Invasive Sentinel Lymph Node Dissection in Prostate Cancer

2023 · Jose M. Abascal Junquera, Nina N. Harke, et al. · Clinical Nuclear Medicine · 14

Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with transperineal prostate biopsies

2024 · Juan Morote, Nahuel Paesano, et al. · International braz j urol · 12

A Diagnostic Accuracy Study of Targeted and Systematic Biopsies to Detect Clinically Significant Prostate Cancer, including a Model for the Partial Omission of Systematic Biopsies

2023 · Juan Morote, Natàlia Picola, et al. · Cancers · 12

PDF

Braquiterapia de baja tasa (I125) en el cáncer de próstata localizado: Resultados preliminares a 5 años

2005 · Pedro J. Prada, Miguel Hevia, et al. · Archivos Españoles de Urología · 12

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer

2023 · Juan Morote, Ángel Borque-Fernando, et al. · European Urology Open Science · 11

Adrenalectomía laparoscópica transperitoneal: resultados tras 70 procedimientos

2008 · Miguel Hevia Suárez, Jose M. Abascal Junquera, et al. · Archivos Españoles de Urología · 11

Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia

2024 · Juan Morote, Ángel Borque-Fernando, et al. · Urologic Oncology Seminars and Original Investigations · 10

Sentinel Lymph Node Biopsy in Prostate Cancer Patients: Results From an Injection Technique Targeting the Index Lesion in the Prostate Gland

2022 · Lluís Fumadó, Jose M. Abascal, et al. · Frontiers in Medicine · 10

PDF

A risk‐organised model for clinically significant prostate cancer early detection

2023 · Juan Morote, Ángel Borque‐Fernando, et al. · BJUI Compass · 9

PDF

Works count: 87

Citation count: 989

H-index: 16

I10-index: 25